Anionic or cationic dendrimer antimicrobial or antiparasitic compositions

• US 7,572,459 B2
• Filed: 08/26/2002
• Issued: 08/11/2009
• Est. Priority Date: 09/14/1998
• Status: Expired due to Fees

• Current Assignee: Starpharma Pty Ltd. (Starpharma Holdings Ltd.)
• Original Assignee: Starpharma Pty Ltd. (Starpharma Holdings Ltd.)
• Inventors: Holan, George, Matthews, Barry Ross
• Primary Examiner(s): Padmanabhan; Sreeni
• Assistant Examiner(s): Carter; Kendra D
• Application Number:
  US10/227,538
• Publication Number:
  US 20030129158A1
• Time in Patent Office: 2,542 Days
• Field of Search: 424/400, 424/78.17, 424/78.27, 424/78.29, 424/405, 525/540, 525/512, 525/417, 525/418, 514/579
• US Class Current: 424/405
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.

Claims

1. A method of treating an infection by an internal parasitic pathogen in a human subject comprising administering to the subject an active agent consisting of an effective amount of a dendrimer comprising (i) a polyvalent core covalently bonded to at least two dendritic branches, extending through at least two generations;

and (ii) a plurality of terminal groups, wherein at least one of said terminal groups has an anionic- or cationic-containing moiety covalently bonded thereto, wherein the dendrimer exhibits an inhibitory effect on the parasitic pathogen, wherein the parasitic pathogen is selected from the group consisting of nematodes, trematodes, cestodes, Trypanosoma species, and Plasmodium species and wherein the dendrimer is the sole active agent.

2. A method according to claim 1, wherein said dendrimer is a polyamidoamine dendrimer based on an ammonia core.

3. A method according to claim 1, wherein said dendrimer is a polyamidoamine dendrimer based on an ethylene diamine core.

4. A method according to claim 1, wherein said dendrimer is a polylysine dendrimer based on a benzhydrylamine core.

5. A method according to claim 1, wherein said dendrimer is a poly(propyl eneimine) dendrimer.

6. A method according to claim 1, wherein said dendrimer is a polyionic dendrimer of the general formula I:

7. A method according to any of claim 1, wherein in said dendrimer said anionic- or cationic-containing moiety or moieties are bonded to amine, sulfhydryl, hydroxy or other reactive terminal groups of the dendrimer by amide, thiourea, urea, amide, alkylamine, ether, thioether, carbamate, ester, or other suitable linkages.

8. A method according to claim 1, wherein in said dendrimer said anionic- or cationic-containing moieties are selected from the group consisting of sulfonic acid-containing moieties, carboxylic acid-containing moieties (including neuraminic and sialic acid-containing moieties and modified neuraminic and sialic acid-containing moieties), boronic acid-containing moieties, phosphoric and phosphonic acid-containing moieties (including esterified phosphoric and phosphonic acid-containing moieties), primary, secondary, tertiary or quatemary amino-containing moieties, pyridinium -containing moieties, guanidinium-containing moieties, amidinium-containing moieties, phenol-containing moieties, heterocycles possessing acidic or basic hydrogens, and zwittenonic-containing moieties.

9. A method according to claim 1, wherein in said dendrimer the moiety or moieties which are bonded to amino or other reactive terminal groups of the dendrimer are selected from the following groups, in which n is zero or an integer of from 1 to 20:

10. The method according to claim 1, wherein said administering comprises systemic administration of said dendrimer.

11. A method according to claim 1, wherein said dendrimer is selected from the group consisting of:

i. alkylsulfonic acid terminated dedrimers;

ii. sulfoacetamide terminated dendrimers;

iii. sulfosuccinamic acid terminated dendrimers;

iv. N-(2-sulfoethyl) succinamide terminated dendrimers;

v. 4-sulfophenylthiourea terminated dendrimers;

vi. 3,6-di-sulfonaphthylthiourea terminated dendrimers;

vii. 4-sulfonaphthylthiourea terminated dendrimers;

viii. 3,5-di-sulfophenylthiourea terminated dendrimers;

ix. 3,6,8-tri-sulfonaphthylthiourea terminated dendrimers;

x. 4-(sulfomethyl) benzamide terminated dendrimers;

xi. 4-sulfobenzamide terminated dendrimers;

xii. N-(4-sulfophenyl) propanamide terminated dendrimers;

xiii. 4-sulfophenylurea terminated dendrimers;

xiv. N,N,N-tri-methylglycinamide terminated dendrimers;

xv. 4-trimethylammonium benzamide terminated dendrimers;

xvi. 4-(trimethylammoniummethyl)benzamide terminated dendrimers;

xvii. N-(2-acetoxyethyl)-N,N-(dimethylammonium)methyl-carboxamide terminated dendrimers;

xviii. guanidino terminated dendrimers;

xix. 4-([1,4,8,11-tetraazacyclotetradecane]methyl)benzamide terminated dendrimers;

xx. 4-carboxy-3 -hydroxy-benzylamine terminated dendrimers;

xxi. 4-carboxyphenylthiourea terminated dendrimers;

xxii. 3,5-dicarboxyphenylthiourea terminated dendrimers;

xxiii. 4-phosphonooxyphenyithiourca terminated dendrimers;

xxiv. 4-(phosphonomethyl )phenylthiourea terminated dendrimers;

xxv. ethyl-4-(phosphonomethyl)phenylthiourea terminated dendrimers;

xxvi. (8-octanamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero-α

-D-galacto-2-nonulopyranosidoic acid terminated dendrimers;

xxvii. (11 -undecanamido)-5-acetamido-3 ,5-dideoxy-2-thio-D-glycero-α

-D-galacto-2-nonulopyranosidoic acid terminated dendrimers;

xxviii. (acetamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero-α

-D-galacto-2-nonulopyranosidoic acid terminated dendrimers;

xxix. (4-butanamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero-α

-D-galacto-2-nonulopyranosidoic acid terminated dendrimers;

xxx. (4-methylbenzamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero-α

-D-galacto-2-nonulopyranosidoic acid terminated dendrimers;

xxxi. (8-octanamido)-4-azido-5-acetamido-3,4,5-trideoxy-2-thio-D-glycero-α

-D-galacto-2-nonulopyranosidoic acid terminated dendrimers;

xxxii. (8-octanamido)-4-amino-5-acetamido-3,4,5-tideoxy-2-thio-D-glycero-α

-D-galacto-2-nonulopyranosidoic acid terminated dendrimers;

xxxiii. 4-benzamidoboronic acid terminated dendrimers;

xxxiv. 3,5-dicarboxyphenylthiourea terminated dendrimers;

xxxv. 4-phosphonooxyphenylthiourea terminated dendrimers;

xxxvi. 4-phosphonophenylthiourea terminated dendrimers;

xxxvii. 4,6-diphosphononaphthylthiourea terminated dendrimers;

xxxviii. fluoresceinthiourea terminated dendrimers;

xxxix. (phenyl-3-boronic acid)-thiourea terminated dendrimers;

xl. pyridinium dodecylcarboxamide terminated dendrimers; and

xli. saccharin terminated dendrimers;

xlii. 2-(trifluoromethyl)benzimidazole-5-thiourea terminated dendrimers;

xliii. 2-carboxy-3-hydroxy-phenylamide terminated dendrimers;

xliv. 2-carboxy-6-hydroxy-phenylamide terminated dendrimers;

xlv. N,N-dimethyl-N-dodecylammonium-N-ethylurea terminated dendrimers;

xlvi. 4-(pyridiniummethyl )benzamide terminated dendrimers;

xlvii. 3,6-disulfo-1-naphthoxyacetamide terminated dendrimers;

xlviii. 3,5-diphosphophenylthiourea terminated dendrimers;

xlix. N,N-dimethyl-N-dodecylglycinamide terminated dendrimers;

l. N-dodecylisonicotinamide terminated dendrimers;

li. succinamide terminated dendrimers;

lii. N-(3,6,8-trisu 1 fonaphthyl)succindiamide terminated dendrimers;

liii. N-(3,6-disulfonaphthyl )succindiamide terminated dendrimers;

liv. 3,5-dicarboxybenzamide terminated dendrimers;

lv. 4-phosphonooxybenzamide terminated dendrimers;

lvi. 4-phsophonobenzamide terminated dendrimers.